NeuroPace Inc
NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation.
NPCE Nasdaq
SEC CIK 1528287
Follow NeuroPace
Weekly email: filings, results
Revenue, last quarter
$23.1M
−1.1% vs same quarter last year
Net income
−$3.3M
+5.7% vs same quarter last year
EPS, diluted
−$0.10
+9.1% vs same quarter last year
Operating cash flow
−$2.8M
−42.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $100M | −$21.5M |
| FY24 | $79.9M | −$27.1M |
| FY23 | $65.4M | −$33M |
| FY22 | $45.5M | −$47.1M |
| FY21 | $45.2M | −$36.1M |
| FY20 | $41.1M | −$24.3M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 77.2% | −16.3% | −21.5% |
| FY24 | 73.9% | −27.1% | −34% |
| FY23 | 73.6% | −41.5% | −50.4% |
| FY22 | 71.4% | −89.6% | −103.4% |
| FY21 | 74% | −52.5% | −79.9% |
| FY20 | 73.6% | −31.7% | −59% |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$11.3M |
| FY24 | −$18.3M |
| FY23 | −$19.9M |
| FY22 | −$37.5M |
| FY21 | −$25M |
| FY20 | −$21.7M |
| FY19 | - |
- NeuroPace
- Healthcare median
Show the numbers
| Year | NeuroPace | Healthcare median |
|---|---|---|
| FY25 | −21.5% | −30.6% |
| FY24 | −34% | −47% |
| FY23 | −50.4% | −58% |
| FY22 | −103.4% | −80.4% |
| FY21 | −79.9% | −71.8% |
| FY20 | −59% | −62.2% |
| FY19 | - | −46.2% |